Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxylamine SCHEMBL160443 | 1.00 | BLM (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL17540680 | 1.00 | BLM (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL30116312 | 0.91 | CHRM2 (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL30702275 | 0.91 | CHRM2 (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL12959067 | 0.91 | CHRM2 (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL4709 | 0.91 | CHRM2 (1.00) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL17047020 | 0.90 | CHRM2 (0.97) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL2529254 | 0.85 | CYP2D6 (0.72) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Doxylamine SCHEMBL29538969 | 0.84 | CYP2D6 (0.71) | BLMCYP2D6CHRM2CHRM1CHRM4 | |
| Pyrilamine SCHEMBL3134257 | 0.83 | CYP2D6 (0.68) | BLMCYP2D6CHRM2CHRM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4590371-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | Scientific Horizons consulting LLC (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2024064885-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2024-03-28 | — | — | WO | claimed |
| US-20190282792-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X MEDICAL NV (BE) | 2019-09-19 | — | — | US | claimed |
| EP-3487519-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X Medical NV (BE) | 2019-05-29 | — | — | EP | claimed |
| EP-2732160-B1 | SELF ADJUSTABLE CONTINUOUSLY VARIABLE POWER TRANSMISSION SYSTEM WITH A REAL TIME VARIABLE FLOW PUMP. | BOTSIS NIKOLAOS (GR) | 2018-02-21 | — | — | EP | claimed |
| WO-2018015467-A1 | COMPOUNDS FOR USE IN METHODS FOR TREATING GLAUCOMA AND RETINAL DISEASES | P&X MEDICAL NV (BE) | 2018-01-25 | — | — | WO | claimed |
| EP-2732160-A2 | SELF ADJUSTABLE CONTINUOUSLY VARIABLE POWER TRANSMISSION SYSTEM WITH A REAL TIME VARIABLE FLOW PUMP. | BOTSIS, Nikolaos (GR) | 2014-05-21 | — | — | EP | claimed |
| WO-2013001319-A2 | SELF ADJUSTABLE CONTINUOUSLY VARIABLE POWER TRANSMISSION SYSTEM WITH A REAL TIME VARIABLE FLOW PUMP. | BOTSIS NIKOLAOS (GR) | 2013-01-03 | — | — | WO | claimed |
| EP-0138882-A1 | IMPROVED ORGANOSOLV PROCESS FOR HYDROLYTIC DECOMPOSITION OF LIGNOCELLULOSIC AND STARCH MATERIALS | O'SHAUGHNESSY, James Patrick (US) | 1985-05-02 | — | — | EP | claimed |
| WO-1984003304-A1 | IMPROVED ORGANOSOLV PROCESS FOR HYDROLYTIC DECOMPOSITION OF LIGNOCELLULOSIC AND STARCH MATERIALS | SHAUGHNESSY JAMES PATRICK O (US) | 1984-08-30 | — | — | WO | claimed |
| US-20260117232-A1 | ANTISENSE OLIGONUCLEOTIDE, COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF FOR EXON SKIPPING | ASOCURA PHARMACEUTICALS SUZHOU CO., LTD. (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260043797-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS AND USES THEREOF | SEER INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-0152432-A1 | SUSTAINED RELEASE METHOD AND PRODUCT. | SCHERER CORP R P (US) | 1985-08-28 | — | — | EP | disclosed |
| WO-1985000516-A1 | SUSTAINED RELEASE METHOD AND PRODUCT | R. P. SCHERER CORPORATION (US) | 1985-02-14 | — | — | WO | disclosed |
| US-4444072-A | Shift mechanism with a neutral stop control for a two-speed transmission | GENERAL MOTORS CORPORATION (US) | 1984-04-24 | — | — | US | disclosed |
| US-4172309-A | Method of correcting deflection defocusing in self-converged color CRT display systems | ZENITH RADIO CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4125057-A | Planetary milling machine | COX KRIS E | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043797-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS AND USES THEREOF | SRMS, PTMS, CTSS | BLM 4320/4885CYP2D6 4701/4885CHRM2 2500/4885 |
| US-20260117232-A1 | ANTISENSE OLIGONUCLEOTIDE, COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF FOR EXON SKIPPING | UPF1, SMN1; SMN2, SNRPA1 | BLM 3300/4885CYP2D6 4340/4885CHRM2 1747/4885 |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | TMCO1, TANK, SARAF | BLM 1048/4885CYP2D6 1791/4885CHRM2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.